Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 September 2021 | Story Dr Nitha Ramnath and Dr Elias Malete

According to Austin (1998:34), language is a tool used by human beings to communicate with each other. All languages have communicative value, meaning, and allow people to share thoughts, feelings, ideas, and exchange knowledge and opinions. No language is better or worse than the other, as all languages are equal in terms of their value and function. On the other hand, language dominance is a social process in which different languages are assigned different levels of importance, such that one language and its speakers carry higher social, economic, and political status than others. Subsequent to this practice, certain speakers struggle for recognition, while others enjoy a broader audience. Addressing language dominance, one needs to remember that language is not naturally hierarchical and that one must respect linguistic diversity and human rights at both individual and collective level. The concept of listening to one another then becomes a challenge, hence the theme: ‘Hearing you hearing me’ is so important in the 21st century.

How then can we as people resist or disrupt language dominance:
• Name and trace the history of language dominance
• The effects of inequity in daily language usage – not hearing each other
• The awareness and significance of multilingualism – learning other languages
• What universities can do and should do on a practical level to promote multilingualism

These are some of the aspects we look forward to discussing in the forthcoming webinar. 

Date: Friday, 17 September 2021
Topic: Hearing you, hearing me
Time: 12:30-14:00

Facilitator:

Dr Elias Malete
Senior Lecturer, African Languages, UFS

Panellists:

Prof Angelique van Niekerk
Associate Professor and Head of Department
Department of Afrikaans and Dutch, German and French
University of the Free State

Prof Nhlanhla Maake
Professor and Language Practitioner of Sesotho

Prof Nobuhle Hlongwa
Dean and Head of the School of Arts
College of Humanities 
University of KwaZulu-Natal


Bios of speakers:

 

Prof Angelique van Niekerk


Prof Angelique van Niekerk copy
Prof Angelique van Niekerk is Associate Professor at the University of the Free State and the HOD in the Department of Afrikaans and Dutch, German and French. Her research focus is on applied linguistics within the field of semantics and pragmatics and on the linguistic nature of advertising communication. She has published many accredited publications within linguistics and communication sciences, in which she integrates her interest in both fields. She has a passion for teaching and (blended learning) course design within language acquisition. This has resulted in different registered SLPs within the department, focusing on Afrikaans as foreign language and Dutch as foreign language.

Prof Nhlanhla Maake

Prof Maake copy

Prof Nhlanhla Maake is currently the Managing Director of the biggest merchandising company in South Africa, a position he has held since 2018. He has just completed a translation of SM Mofokeng’s Pelong ya Ka into English. The book is to be published in London, New York, and Calcutta in 2021 under the Elsewhere Texts series, edited by Gayatri Spivak and Hosam Aboul-Ela. 

He has held several academic positions nationally and globally and has served on several language task teams under the auspices of the Department of Arts and Culture; as a member of the Parish Pastoral Council at Our Lady of Mt Carmel in Thokoza; as a member and chairperson of the Catholic Bible College; as member and acting Chairperson of the English National Language Body of PANSALB; as Council member of the English Academy of Southern Africa; as Council member of the Afrikaanse Taalmuseum en -monument (2015 to 2017); and as Council member of the Wits Council on Education.

Prof Maake was an NRF (National Research Foundation) rated scholar (2006-11) and has held fellowships at Aarhus University (1983), on the Southern African Research Program (Yale University, 1989), Ernest Oppenheimer fellowship (UCT, 1992), and the Distinguished Scholars Programme (Wits, 1993). He was admitted to the Golden Key International Honour Society in 2005. He has presented papers and keynote addresses at more than 80 international and local conferences, is widely published, and has won several literary awards and recognitions. 


Prof Nobuhle Hlongwa


Prof Hlongwa  copy

Prof Nobuhle Hlongwa is the Dean and Head of the School of Arts in the College of Humanities at the University of KwaZulu-Natal. She is the former Dean of Teaching and Learning in the College of Humanities and was the acting Dean and Head of the School of Religion, Philosophy and Classics for six months in 2016. Rated by the National Research Foundation (NRF) as a C2-rated social scientist for five years, Prof Hlongwa has more than 30 publications, including research articles, books, book chapters, and conference proceedings. She is currently a member of the Academic Advisory Board of African Languages on the Bloemfontein Campus, and a member of the Board of Directors of the International Congress of Onomastic Sciences (ICOS). She is a representative of the University of KwaZulu-Natal in the Community of Practice for the Teaching and Learning of African Languages (CoPAL), which forms part of the devolved governance structure of Universities South Africa (USAf). 

She was a member of the Ministerial Advisory Panel on the development of African Languages in Higher Education. She completed her first post-doctoral supervision in June 2018.  She is a member of the advisory board of the South African Journal of African Languages (SAJAL). She is assistant editor of the Alternation Journal. She is a reviewer for the National Research Foundation (NRF), as well as for a number of academic journals. 




News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept